SEMHF (Siemens Healthineers AG) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SEMHF Siemens Healthineers AG SEMHF
84 GF Score
Price $46.00
GF Value $59.20
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Siemens Healthineers AG Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

SEMHF
84GF Score
Siemens Healthineers AG SEMHF
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Siemens Healthineers AG (SEMHF) Overvalued in 2026?

Based on GuruFocus' analysis, Siemens Healthineers AG stock appears to be undervalued. The current stock price of $46.00 is trading 22.3% below its estimated GF Value™ of $59.20. GuruFocus considers Siemens Healthineers AG to be Modestly Undervalued.

Key valuation signals for SEMHF:

  • Interest Received:
  • GF Value™: $59.20 vs. price of $46.00 (22.3% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the SEMHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Siemens Healthineers AG Business Description

Address Siemensstrasse 3, Forchheim, BY, DEU, 91301
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (56% of sales in fiscal 2025) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (18% of sales) offers radiotherapy and other oncology solutions. The diagnostics segment (19%) includes in vitro diagnostics and point-of-care diagnostics. The advanced therapies (now part of precision therapy) segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The Americas represents 44% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific, including China (11%), the remainder.
84GF Score

Get the complete analysis for SEMHF

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.00
Price
$59.20
GF Value